Vilin Bio Med Limited appointed Ms. Neha Lahoti as its Company Secretary and Compliance Officer effective June 27, 2026, following the resignation of Ms. Anjali Choudhary. The Board of Directors approved the appointment during a meeting held at the company's registered office on Saturday. Ms. Lahoti is an Associate Member of the Institute of Company Secretaries of India (ICSI) and a Commerce Graduate with experience in Corporate Laws, Corporate Governance, and SEBI Listing Regulations.

Ms. Anjali Choudhary resigned from the position of Company Secretary and Compliance Officer due to personal reasons, effective from the closing of business hours on June 27, 2026. The Board placed on record its appreciation for her contributions during her tenure. The company confirmed that Ms. Lahoti is not debarred from holding office by any regulatory authority.

Key Management Changes

The following table summarizes the changes in the company's key managerial personnel:

The disclosures were made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board meeting commenced at 3:00 P.M. and concluded at 5:00 P.M. on June 27, 2026.

Vilin Bio Med reported a 763% surge in net profit to ₹192.88 lakh for the financial year ended March 31, 2026, driven by a significant increase in revenue from operations. The company's revenue from operations jumped 185% to ₹4,226.30 lakh from ₹1,480.99 lakh in the previous year. Earnings per share (EPS) for the year improved to ₹1.37 from ₹0.16 in FY25.

The Board of Directors approved the audited financial results for the year and half-year ended March 31, 2026, in a meeting held on May 30, 2026. The results were reviewed by the Audit Committee and audited by the Statutory Auditors, PPKG & Co, Chartered Accountants. The auditors issued an unmodified opinion on the standalone financial results.

Total expenses for FY26 increased to ₹3,942.33 lakh from ₹1,497.26 lakh in the prior year, primarily due to higher costs of materials consumed, which rose to ₹3,762.74 lakh. Finance costs decreased significantly to ₹6.88 lakh from ₹84.51 lakh. The company's profit before tax for the year stood at ₹284.09 lakh, compared to ₹30.58 lakh in the previous year.

Financial Performance for FY26

Capital Allocation and Fund Utilisation

During the financial year, the company allotted 13,00,000 equity shares on a preferential basis at a face value of ₹10 and a premium of ₹16 per share, raising ₹338.00 lakh. The company confirmed that there was no deviation or variation in the utilisation of funds raised through the preferential issue. Of the total amount raised, ₹197.93 lakh has been utilised, with a balance of ₹140.07 lakh maintained with a scheduled commercial bank.

The trading window for dealing in the company's securities, which was closed from April 1, 2026, will open 48 hours after the declaration of the audited standalone financial results.